InfuSystem anticipates pro forma annual revenue growth between six percent and eight percent for 2026 [1].
This guidance comes as the company navigates a critical transition period involving contract restructuring and the migration of its Wound Care business. The stability of its enterprise resource planning (ERP) system is now a primary operational focus to ensure long-term scalability.
Carrie Lachance, President, CEO and Director of InfuSystem, said the company reported first quarter 2026 revenue of $33.7 million [1]. She said the quarter was a reflection of disciplined execution and meaningful strategic progress [2].
Financial results for the full year 2026 include a 24% increase in adjusted EBITDA, reaching $31.5 million [3]. The company also reported strong operating cash flow of $7.1 million [3]. Lachance said the firm achieved top line growth of seven percent [3].
These figures follow a period of significant volatility. The company's GAAP revenue for the prior year, 2025, was just over $1 million [1]. The current shift toward pro forma growth targets suggests a move toward stabilizing the business model after the 2025 fiscal year.
Management is currently prioritizing the stabilization of the ERP go-live process. This technical transition is occurring alongside the aforementioned contract restructuring to optimize how the company manages its healthcare service delivery.
“Today, we reported first quarter of 2026 revenue of $33.7 million.”
InfuSystem is attempting to pivot from a low-revenue 2025 to a period of sustainable growth by upgrading its backend infrastructure. The focus on ERP stabilization indicates that the company's ability to meet its 6% to 8% growth target depends heavily on its technical capacity to manage data and contracts efficiently during its Wound Care business migration.
